FDG-PET/CT helps stage men with breast cancer, too
Assessing breast cancer in men is an uncommon clinical use for FDG-PET/CT, but the hybrid modality achieves results comparable to those in women in regard to accurate staging of the disease, according to a study published online September 21 in the Journal of Nuclear Medicine. {read more here}
BlueCross BlueShield of Tennessee announced it will expand Medicare coverage for cardiac PET, according to the Society for Nuclear Medicine and Molecular Imaging (SNMMMI). The change will take effect later this year. {read more here}
The research details how Robert Hicks, MD, from the department of radiology and biomedical imaging at UCSF, and colleagues found that prostate-specific membrane antigen PET could be used to characterize cancer and determine malignancy within a single exam. {read more here}
Positron emission tomography (PET) quantification of tau protein aggregates in the brain with an 18F-labeled tracer called flortaucipir discriminated Alzheimer’s disease from other neurodegenerative diseases with strong though imperfect accuracy, a large, multicenter study found. {read more here}